Of patients with abnormal results: one proceeded to coronary angiography which showed non flow limiting disease and was listed for liver transplantation; two patients with CTCA evidence of high-grade or complete LAD stenosis were deemed too high risk for liver transplantation and not listed. 5 patients were referred

to cardiology who felt the lesions were non flow limiting and were subsequently listed for transplantation. The remaining 2 patients are currently completing transplantation assessment. Of the 36 patients, 31% (11) underwent liver transplantation, 36% (13) remain active on the waiting list, 28% (10) were de-listed after work-up or died on the waiting list and 2 (5%) are currently completing assessment. No coronary events have been observed in any CTCA patient post transplantation. Conclusion: CTCA is a feasible study in high-risk CLD patients undergoing mTOR inhibitor assessment for liver transplantation

and can give additional information beyond that provided by DSE, which in a small number of cases affected suitability for transplantation. The precise role of CTCA in liver transplantation assessment requires further investigation. R WUNDKE, R, MCCORMICK, AND A WIGG Hepatology and Liver Transplant Medicine Unit, Flinders Medical Centre, South Australia. Introduction: A recent Deloitte Access Economics report estimated the economic costs of liver disease in Australia at more than $AUD50 billion per annum. A key recommendation of Copanlisib this report was creation of Chronic Liver Disease Nurse (CLDN) positions in Australia to improve the management of CLD patients. However, there is a paucity of literature describing the role of community-based CLDNs, their effectiveness and economic impacts. In January 2009 the Hepatology and Liver Transplant

Medicine Unit of Flinders Medical Centre initiated the first CLDN positions in Australia. Two advanced practice nurses (1.6 heptaminol FTE) fill the CLDN role. The aims of this paper are therefore to describe the role of these community CLDN positions and to estimate the cost savings from this position. Methods: Key performance indicators were monitored quarterly from Jan 2011 to mid 2013 including presentations to the Emergency Department (ED), admissions to hospital, and outpatient department use. Costs savings, from the a hospital perspective and resulting from saved ED presentations, hospital admissions and medical outpatient visits were estimated using standard hospital accounting practices. Results: CLDN Role: The role of the CLDN is to provide care and support for cirrhotic patients. The program currently cares for 335 patients and has two arms – stable (screening and surveillance) and unstable (case management). The stable program involves arranging and monitoring the results of 6-monthly hepatoma screening, variceal screening and surveillance according to protocols, bone density screening and osteoporosis treatment, and immunisation for hepatitis A and B.